Temovate
Temovate Price range: $ 42,00 through $ 295,00
Back to products
Tenormin
Tenormin Price range: $ 78,00 through $ 580,00

Temsujohn

Price range: $ 55,00 through $ 335,00

Temsujohn is a specialized medication formulated to protect the stomach lining and prevent the formation of gastric ulcers. It is primarily indicated for patients who require long-term treatment with nonsteroidal anti-inflammatory drugs (NSAIDs) for chronic pain or inflammation. The active components work by decreasing the amount of acid that comes into contact with the stomach wall while replenishing protective substances. This proactive approach significantly reduces the risk of gastrointestinal irritation and more serious complications during ongoing therapy. Temsujohn provides essential support for digestive health, ensuring that patients can manage their primary conditions with greater comfort and safety.

Active substance: Tamsulosin
SKU: Temsujohn Category:
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

Temsujohn belongs to the class of targeted antineoplastic agents designed to inhibit specific cellular pathways involved in abnormal cell proliferation. In the United States, this medication is available strictly by prescription (Rx) and must be administered under the direct supervision of a qualified oncology specialist. Healthcare providers prescribe Temsujohn following a comprehensive clinical evaluation and confirmation of appropriate therapeutic indications.

Understanding the pharmacologic profile, administration protocol, and potential side effects of Temsujohn is essential for patient safety and optimal therapeutic management. This overview provides verified medical information derived from standard regulatory frameworks and clinical guidelines in accordance with US federal and state regulations.

Property Details
Drug name Temsujohn
Therapeutic class Antineoplastic mTOR inhibitor
Dosage form Solution for intravenous infusion
Route of administration Intravenous (IV)
Prescription status Prescription only (Rx)
Primary purpose Targeted treatment of advanced renal cell carcinoma

Pharmacologic Profile and Indications

Mechanism of action

Temsujohn operates as a selective inhibitor of the mammalian target of rapamycin (mTOR), an intracellular kinase that plays a critical role in regulating cell growth, proliferation, and survival. Upon administration, the active drug binds to an intracellular protein (FKBP-12), forming a complex that inhibits the activity of mTOR complex 1 (mTORC1). This inhibition blocks downstream signaling cascades required for protein translation and cell cycle progression from the G1 to the S phase. Furthermore, suppression of the mTOR pathway reduces the expression of vascular endothelial growth factor (VEGF), thereby inhibiting tumor angiogenesis and restricting the blood supply to neoplastic tissues.

What it’s used for

Temsujohn is indicated for the treatment of advanced renal cell carcinoma (RCC). It is utilized primarily in patients who require systemic targeted therapy to suppress disease progression. If prescribed for off-label indications outside the scope of FDA-approved labeling, such usage must be explicitly evaluated by the attending oncologist based on clinical trial evidence or specialized treatment protocols. Patients should discuss the clinical rationale with their provider to understand why Temsujohn has been chosen as part of their treatment plan.

How it’s absorbed and eliminated

Because Temsujohn is administered via intravenous infusion, systemic absorption is immediate and complete. The drug undergoes extensive hepatic metabolism primarily mediated by the cytochrome P450 enzyme system, specifically the CYP3A4 pathway. This metabolic process yields major active metabolites, including sirolimus, which contribute to the overall therapeutic activity. Elimination occurs predominantly through the biliary system into the feces, while a small percentage is cleared by the kidneys. The elimination half-life and total body clearance depend on individual metabolic capacity, organ function, and concurrent medications.

Clinical Administration and Safety Profile

Dosing schedule

The administration of Temsujohn requires a precise schedule established by the medical oncology team. The standard dose is calculated individually based on clinical parameters, laboratory values, and treatment tolerance. Injections are typically given once weekly as an intravenous infusion over a specified timeframe in a clinical setting, such as a outpatient oncology center in Chicago or Houston. Prior to each infusion, patients frequently receive pre-medication, such as an intravenous antihistamine (e.g., diphenhydramine), to decrease the incidence and severity of hypersensitivity reactions. Treatment duration and dose adjustments are managed strictly by the prescribing physician.

Compatibility with other medicines

Temsujohn interacts significantly with medications that alter the metabolic activity of hepatic enzymes. Co-administration with strong CYP3A4 inhibitors (such as ketoconazole, clarithromycin, or itraconazole) can increase blood concentrations of Temsujohn, elevating the risk of toxic side effects. Conversely, concurrent use of strong CYP3A4 inducers (such as rifampin, carbamazepine, or St. John’s wort) may substantially lower systemic exposure, reducing therapeutic efficacy. Combining Temsujohn with angiotensin-converting enzyme (ACE) inhibitors increases the risk of angioedema. Patients must disclose all prescription drugs, over-the-counter medications, and dietary supplements before starting therapy.

Adverse reactions

The administration of Temsujohn is associated with a spectrum of adverse reactions ranging from mild to severe. Common clinical adverse reactions include generalized fatigue, stomatitis, mucosal inflammation, skin rash, nausea, diarrhea, peripheral edema, and loss of appetite. Laboratory abnormalities are also frequent, including hyperlipidemia, hypercholesterolemia, hyperglycemia, elevated liver enzymes, anemia, leukopenia, and thrombocytopenia. Less frequent but severe complications include non-infectious pneumonitis, impaired wound healing, bowel perforation, severe hypersensitivity reactions, and serious opportunistic infections due to systemic immunosuppression.

Important precautions

Prior to initiating Temsujohn, patients must undergo comprehensive clinical evaluations, including baseline laboratory testing. Regular monitoring of complete blood counts, renal and liver function panels, blood glucose levels, and serum lipid profiles is mandatory throughout treatment. Because Temsujohn can suppress immune function, active infections must be resolved before starting therapy. Patients experiencing respiratory symptoms, such as a new or worsening cough or shortness of breath, must notify their medical provider immediately, as these may indicate drug-induced interstitial lung disease.

Special populations

Temsujohn can cause fetal harm when administered to pregnant women due to its mechanism of cellular inhibition. Effective contraception must be utilized by female patients of reproductive potential during treatment and for several months following the final dose. Male patients with female partners of reproductive potential should also utilize effective contraception during treatment. Breastfeeding is not recommended during therapy due to potential severe adverse reactions in nursing infants. Patients with underlying hepatic impairment require reduced dosages and close therapeutic monitoring. The safety and efficacy of Temsujohn in pediatric patients have not been established.

If you skip a dose

Since Temsujohn is administered by healthcare professionals in a medical setting, missing a dose typically results from scheduling changes or medical interruptions. If an appointment is missed, the patient should contact the oncology clinic immediately to reschedule the infusion. Patients should not attempt to adjust their dosing schedule independently. The medical team will determine the safest interval for the next dose to maintain continuous therapeutic management without increasing the risk of adverse reactions.

Storage and expiration

Unopened vials of Temsujohn must be stored in a controlled refrigerated environment between 2°C and 8°C (36°F and 46°F) and kept in the original carton to protect the medication from light exposure. Diluted solutions prepared for infusion must be handled according to strict clinical oncology standards and administered within specified time limits. Hazardous drug handling rules apply. Medication should never be used past the expiration date printed on the clinical packaging.

Red flags

Patients undergoing treatment must be vigilant for severe complications that demand urgent medical intervention. Immediate reporting of red flag symptoms allows oncology teams to initiate prompt supportive care or modify treatment.

Symptom Category Immediate Action Required
Respiratory symptoms Sudden onset of dyspnea, persistent dry cough, chest tightness, or fever.
Hypersensitivity reaction Facial swelling, swelling of the lips/tongue, urticaria, or difficulty swallowing.
Severe infection signs High fever, chills, severe sore throat, or localized redness and warmth.
Gastrointestinal emergency Severe abdominal pain, persistent vomiting, or bloody stools.
Severe skin/wound changes Surgical site dehiscence, severe rash, blistering, or skin peeling.

Common Questions

What should I do if I develop a dry cough or shortness of breath during treatment?

New or worsening pulmonary symptoms must be evaluated by your healthcare provider without delay. Temsujohn has been associated with non-infectious pneumonitis, a serious condition requiring medical evaluation, radiographic imaging, and potential dose interruption or treatment discontinuation. Do not attempt to treat respiratory symptoms with over-the-counter cough remedies without explicit instruction from your oncologist.

Can I receive routine vaccinations while taking Temsujohn?

Live vaccines (such as live attenuated influenza, MMR, or yellow fever vaccines) must be avoided during treatment with Temsujohn due to the drug’s immunosuppressive properties, which increase the risk of vaccine-derived infection. Non-live or inactivated vaccines may be administered, but the immune response may be diminished. Always consult your oncology team before scheduling any vaccination.

How does Temsujohn affect blood sugar and lipid levels?

Temsujohn frequently causes elevations in blood glucose, triglycerides, and cholesterol levels by altering metabolic pathways. Your healthcare team will monitor your blood chemistry regularly through routine blood tests. In some cases, dietary adjustments or initiation of lipid-lowering or glucose-lowering medications may be required during the treatment course.

Is it safe to consume grapefruit or herbal supplements like St. John’s wort while on this drug?

No. Grapefruit, grapefruit juice, and strong enzyme inhibitors can dangerously increase the blood concentration of Temsujohn. Conversely, herbal supplements like St. John’s wort induce metabolic enzymes and significantly lower drug levels, rendering the treatment less effective. Always inform your clinical team of all dietary items and supplements you consume.

What precautions should be taken regarding wound healing before undergoing surgery?

Because Temsujohn inhibits cellular proliferation and angiogenesis, it can significantly impair normal wound healing. If elective surgery or invasive dental procedures are planned, treatment with Temsujohn may need to be temporarily interrupted before and after the procedure. Consult your prescribing doctor to coordinate the timing of surgical interventions safely.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice. Always consult your healthcare provider before starting or changing any treatment.

Additional information
Dosage

0.2mg

,

0.4mg

Package

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία